Loading…
← CockpitCompetitor Analysis › SPRY ARS Pharmaceuticals, Inc.Open in the cockpit ↗

ARS Pharmaceuticals, Inc.SPRYCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 12
Mkt cap
$371M
US dollars, full cap
Free float
66%
of shares outstanding
$/day
$8.24M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.8%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$3.69
1D+1.1%
1W-6.6%
1M-14.0%
3M-33.0%
6M-52.7%
YTD-68.3%
1Y-49.6%
ATR %9.3%
Beta1.84
52w lowhigh71.9% off high

What ARS Pharmaceuticals does

Employees: 163

ARS Pharmaceuticals at a glance

Size ARS Pharmaceuticals (SPRY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $371M, the 2901st largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.69 on 18 Nov 2026.

Performance Over six months the shares fell 52.7%, against -22.0% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 19 in its peer set.

Growth Revenue fell 14.4% over the last twelve months (peer median -1.1%); the operating margin is -161.5% (peer median -2.2%).

Valuation It trades at 2.9× enterprise value to sales against a peer median of 4.4× (6th cheapest of 18).

Short interest Short interest is 18.9% of the free float (30 Oct 2026).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010021 May 202621 Aug 202618 Nov 2026Peer median 79SPRY 45
Six months, rebased to 100: ARS Pharmaceuticals against the median of its 20 peers (local-currency closes).

ARS Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$122M$84.3M$89.1M$30,000$1.32M
Revenue growth—-5%+297,063%-98%—
Gross profit$86.8M$63.9M$88.0M-$43,000$997,000
EBITDA-$196M-$178M-$2.88M-$67.4M-$35.2M
Net income-$200M-$171M$8.00M-$54.4M-$34.7M
Free cash flow-$183M-$171M$13.0M-$59.4M-$40.3M
Capital expenditure$0$339,000$563,000$175,000$199,000
Total debt$122M$97.0M$42,000$274,000$481,000

Quarterly statements and history in the cockpit →

ARS Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-40%-20%0%002872MPLTPBYI301111688399005690IRD3010894552UNICHEMLAB4569459230053442C000153AVTX300452SPRY6-month return →1-month return →
Up and to the right = strong over both horizons. ARS Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×25×50×75×002872PBYI005690IRD4552002868SHUKRAPHAR42CSPRYRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ARS Pharmaceuticals is the large dot.

ARS Pharmaceuticals competitors and peer comparison

How ARS Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ARS Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureSPRYPeer medianRank in peer set
1-month return-14.0%-13.3%10th lowest of 20
6-month return-52.7%-22.0%6th lowest of 19
Distance from 52-week high-71.9%-38.5%3rd lowest of 21
Revenue growth (TTM)-14.4%-1.1%6th lowest of 18
Operating margin-161.5%-2.2%4th lowest of 19
EV / Sales2.9×4.4×6th cheapest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%2.9×n/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%4.9×22.2%-15.7%
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
Puma Biotechnology PBYIUnited States$373M+3%+9%11%1.2×0.1%+0.3%
6467 6467.TWTaiwan$368Mn/an/a-2,618%1,407.9×n/an/a
Guangdong Lifestrong Pharmacy 301111.SZChina$368M-33%+7%-2%7.2×n/an/a
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%4.4×n/an/a
Pharmicell 005690.KSSouth Korea$364M-55%+46%32%3.0×-7.9%+24.8%
Opus Genetics IRDUnited States$379M-22%-46%-778%41.2×n/an/a
Tuoxin Pharmaceutical 301089.SZChina$363M-28%+17%-20%5.3×n/an/a
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%2.9×n/an/a
Unichem Laboratories UNICHEMLAB.NSIndia$361M+28%+6%5%1.6×n/an/a
KYORIN Pharmaceutical 4569.TJapan$360M-22%-6%2%0.5×6.7%+4.2%
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%6.2×n/an/a
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%3.7×20.9%+28.2%
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%32.0×n/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%71.6×n/an/a
Anhui Fengyuan Pharmaceutical 000153.SZChina$355M-17%-24%3%1.1×3.6%+3.1%
Avalo Therapeutics AVTXUnited States$387M-59%-69%-161,961%n/an/an/a
Anhui Sunhere Pharmaceutical Excipients 300452.SZChina$388M-17%+9%19%2.2×-5.5%+12.2%

Questions

Which companies are ARS Pharmaceuticals's closest peers?
The cockpit's peer set: Tiansheng Pharmaceutical (002872.SZ), MapLight Therapeutics (MPLT), Puma Biotechnology (PBYI), 6467 (6467.TW), Guangdong Lifestrong Pharmacy (301111.SZ), Jiangsu Bioperfectus Technologies (688399.SS), Pharmicell (005690.KS), Opus Genetics (IRD).
Is ARS Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 2.9× against a peer median of 4.4×, 6th cheapest of 18 in its peer set.
How has ARS Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -52.7% against -22.0% for the median peer; over one year -49.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.